| Insiders | Shares | % | Avg Price | Total $ | |
|---|---|---|---|---|---|
| Buys | 0 | ||||
| Sells | 11 | -891 K | 100% | $16.75 | -$14.9 M |
| Net | -11 | -891 K | -100% | -$14.9 M |
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Report Date |
|---|---|---|---|---|---|
| Aladar Szalay | 10%+ Owner | $4.19 M | -$10.6 M | -71.6% | May 13, 2024 |
| Qian Zhang | Associate VP, Research | $1.98 M | Feb 17, 2023 | ||
| John Thomas | Director | $1.71 M | -$346 K | -16.8% | May 29, 2024 |
| Thomas Zindrick | President and CEO, Director | $786 K | -$198 K | -20.1% | May 29, 2024 |
| Caroline Jewett | Head of Quality | $300 K | -$12.2 K | -3.92% | Oct 2, 2023 |
| Gabe Woodward | Director | $175 K | Feb 17, 2023 | ||
| Lourie S. Zak | Chief Financial Officer | $114 K | May 29, 2024 | ||
| Joseph Cappello | VP, Pharmaceutical Development | $81.3 K | -$77.5 K | -48.8% | Sep 11, 2023 |
| Ralph Smalling | Head of Regulatory | $48.8 K | -$22.2 K | -31.3% | May 29, 2024 |
| John W. Smither | Director | $48.2 K | -$18.7 K | -27.9% | May 29, 2024 |
| Mary Mirabelli | Director | $45.6 K | May 29, 2024 | ||
| Sean Ryder | General Counsel | $38.7 K | -$308 K | -88.8% | May 29, 2024 |
| James L. Tyree | Director | $35.6 K | -$119 K | -77% | May 29, 2024 |
| Doug Samuelson | Vice President, Finance | $32.6 K | -$30.8 K | -48.5% | Sep 11, 2023 |
| Yong Yu | VP, Clinical Trial Operations | $9.16 K | -$3.19 M | -99.7% | May 29, 2024 |
| Paul Scigalla | Chief Medical Officer | Jan 25, 2023 |
| Insider | Class | Transaction | % | Value $ | Price $ | Shares | Shares Owned | Date | Ownership |
|---|